glepaglutide

Glepaglutide is a long-acting glucagon-like peptide-2 (GLP-2) analog developed by Zealand Pharma for the treatment of short bowel syndrome (SBS), particularly in patients with intestinal failure who are dependent on parenteral support. It is designed as a ready-to-use, fixed-dose product for subcutaneous administration via autoinjector, typically dosed once or twice weekly. Glepaglutide acts by stimulating the GLP-2 receptor to enhance intestinal absorptive function, promote mucosal growth, and improve nutrient and fluid uptake in patients with SBS. Clinical trials have shown that twice-weekly dosing can significantly reduce the need for parenteral support compared to placebo. The drug has received orphan drug designation from regulatory authorities but has not yet been approved; its New Drug Application was met with a Complete Response Letter from the FDA requesting additional clinical data[1][2][3][5][6][7].

Other names

glepaglutideglepaglutidaglepaglutidum